Corporate Banner
Satellite Banner
RNAi
Scientific Community
 
Join | Sign in
Home>News>This Article
  News
Return

NANOBIOTIX honored at the INVESTOR AWARDS 2013 in the “Young Talent” category

Published: Friday, November 08, 2013
Last Updated: Friday, November 08, 2013
Bookmark and Share
NANOBIOTIX announced it has been awarded the “Young Talent” Award at the INVESTOR AWARDS 2013, referring to a newly listed company.


For access to this article, enter your email address to instantly recieve a Password Reset link.

Please enter your email address below:

Existing users please Sign In here. Don't have an account? Register Here for free access.

Don't have an account? | Register Here


Scientific News
Fighting the Colorado Potato Beetle with RNA
RNA interference protects potato plants against herbivore attack.
Acetate Supplements Shown to Speed Up Cancer Growth
A major compound produced in the gut by host bacteria.
Two Cell-Signaling Molecules Found to Suppress the Spread of Melanoma
Findings advance efforts to identify who would benefit from more aggressive therapy at earliest stages.
Single-Cell, 42-plexed Protein Analysis Achieved with a New Microchip Technology
A novel microdevice capable of detecting 42 unique immune effector proteins has been developed.
MAGE Genes Provide Insight into Optimizing Chemotherapy
UT Southwestern Medical Center scientists have identified a new biomarker that could help identify patients who are more likely to respond to certain chemotherapies.
Researchers Identify ‘Achilles heel’ in Metabolic Pathway
Achilles heel could lead to new lung cancer treatments.
New Resource to Study the Mechanism and Regulation of Autophagy
New online resource will provide an integrated and systems-level database for autophagy research.
Researchers Discover Possible Mechanism for Faster Evolution
Results hold great promise for gene therapy development.
Yale Team Identifies Key Process In Brain Development
miR-107 shown to play essential role in regulating normal brain development.
Cancer Treatment with KU Origins Enters Second Clinical Trial
Cleave Biosciences has begun a Phase 1 clinical trial to evaluate CB-5083.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters